Concepedia

Ching‐Ping Ho

CH

Statistics

Publications

4

Citations

147

H-Index

4

Active since

2009

Affiliations

Bristol-Myers Squibb (United States)(Current)

Ching‐Ping Ho is an author at Bristol-Myers Squibb (United States) specializing in oncology, medicine, and cancer immunotherapy.

Publications per year

2009–2019

4

Publications

4

Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance

Jinqi Liu, Joshua C. Curtin, Dan You et al. · PLoS ONE · 2019 · 59 citations · Full text

, , +17

Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI)

Lalgudi S. Harikrishnan, Jayakumar Warrier, Andrew J. Tebben et al. · Bioorganic & Medicinal Chemistry · 2018 · 36 citations · Full text

, , +12

Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents

Yong Zhang, Yufen Zhao, Andrew J. Tebben et al. · ACS Medicinal Chemistry Letters · 2018 · 28 citations · Full text

, , +17

Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development

Steven Gendreau, Don Hawkins, Ching‐Ping Ho et al. · Molecular Cancer Therapeutics · 2009 · 24 citations

, , +17

1–4 of 4